Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Lilly

Status and phase: Completed; Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: gemcitabine; Drug: Cisplatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00191841

7410

B9E-VI-S327

Details and patient eligibility

About

To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologic or cytologic diagnosis of operable non-small cell lung cancer (IB-IIIA)
• no prior chemotherapy
• WHO criteria for disease status assessment

Exclusion criteria

• Concurrent administration of any other tumor therapy
• pregnant or breast feeding
• serious concomitant disorders

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)